Abstract
Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.
Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.
Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.
Original language | English |
---|---|
Pages (from-to) | 345—364 |
Journal | Drug design, development and therapy |
Volume | 13 |
Publication status | Published - 18 Jan 2019 |
Keywords
- atrial fibrillation
- heat shock protein
- drosophila
- proteostasis
- geranylgeranylacetone